Data by Company within Medical Laboratories Industry
|
|
Marketcap |
Revenues (TTM) |
Net Income (TTM) |
Employees |
Company |
(Millions) |
(Millions) |
(Millions) |
Number |
Iqvia Holdings Inc |
$ 47,292 |
$ 14,984 |
$ 1,358 |
79,000 |
Ge Healthcare Technologies Inc |
$ 40,869 |
$ 16,387 |
$ 1,614 |
- |
Icon Plc |
$ 27,691 |
$ 8,120 |
$ 1,237 |
15,950 |
Koninklijke Philips Nv |
$ 19,243 |
$ 20,349 |
$ -519 |
82,000 |
Laboratory Corporation Of America Holdings |
$ 18,362 |
$ 12,162 |
$ 419 |
75,500 |
Hologic Inc |
$ 18,235 |
- |
$ 881 |
6,944 |
Quest Diagnostics Inc |
$ 14,610 |
$ 9,252 |
$ 908 |
49,000 |
Charles River Laboratories International inc |
$ 13,494 |
$ 4,129 |
$ 480 |
20,000 |
Incyte Corporation |
$ 13,163 |
$ 3,696 |
$ 598 |
2,094 |
Medpace Holdings Inc |
$ 12,636 |
$ 1,886 |
$ 283 |
3,900 |
Exact Sciences Corporation |
$ 10,426 |
$ 2,532 |
$ -204 |
5,361 |
Natera inc |
$ 10,297 |
$ 1,083 |
$ -435 |
2,800 |
Syneos Health Inc |
$ 4,485 |
$ 5,419 |
$ 71 |
25,000 |
Fortrea Holdings Inc |
$ 3,341 |
- |
$ 0 |
- |
Radnet Inc |
$ 3,059 |
$ 1,580 |
$ 29 |
8,700 |
Guardant Health Inc |
$ 1,955 |
$ 564 |
$ -479 |
1,100 |
Veracyte inc |
$ 1,539 |
$ 361 |
$ -74 |
677 |
National Research Corporation |
$ 984 |
$ 149 |
$ 31 |
- |
Viridian Therapeutics Inc |
$ 765 |
$ 0 |
$ -238 |
- |
Science 37 Holdings Inc |
$ 679 |
- |
$ 77 |
- |
Fulgent Genetics Inc |
$ 663 |
$ 285 |
$ -65 |
284 |
Nano x Imaging Ltd |
$ 563 |
$ 9 |
$ -113 |
- |
Caredx Inc |
$ 545 |
$ 280 |
$ -190 |
446 |
Omniab Inc |
$ 523 |
$ 88 |
$ -50 |
- |
Castle Biosciences Inc |
$ 506 |
$ 220 |
$ 0 |
200 |
Lightwave Logic Inc |
$ 476 |
- |
$ -21 |
10 |
Absci Corp |
$ 452 |
$ 7 |
$ -106 |
- |
Maxcyte inc |
$ 442 |
$ 41 |
$ -38 |
- |
Mdxhealth Sa |
$ 420 |
$ 37 |
$ -44 |
- |
Somalogic Inc |
$ 393 |
$ 82 |
$ -130 |
- |
Celcuity Inc |
$ 390 |
- |
$ -49 |
- |
Nuoncology Labs Inc |
$ 322 |
- |
$ 0 |
- |
Sera Prognostics Inc |
$ 290 |
$ 0 |
$ -38 |
- |
Zymergen Inc. |
$ 251 |
$ 15 |
$ -365 |
- |
Inotiv Inc |
$ 235 |
$ 585 |
$ -33 |
- |
Butterfly Network inc |
$ 220 |
$ 66 |
$ -134 |
- |
Fresh2 Group Ltd |
$ 167 |
$ 2 |
$ -15 |
- |
Luna Innovations Inc |
$ 157 |
$ 114 |
$ -2 |
236 |
Bionexus Gene Lab Corp |
$ 124 |
$ 10 |
$ -1 |
- |
Biodesix Inc |
$ 117 |
$ 44 |
$ -63 |
- |
Renalytix Plc |
$ 82 |
$ 1 |
$ -34 |
- |
Personalis Inc |
$ 78 |
$ 71 |
$ -113 |
- |
Enzo Biochem Inc |
$ 62 |
- |
$ 33 |
412 |
Exagen Inc |
$ 29 |
$ 53 |
$ 0 |
- |
Akumin Inc |
$ 26 |
$ 738 |
$ -258 |
- |
Dermtech Inc |
$ 23 |
$ 13 |
$ -110 |
- |
Centogene N v |
$ 19 |
$ 53 |
$ -36 |
500 |
Psychemedics Corp |
$ 17 |
$ 22 |
$ -4 |
- |
American Shared Hospital Services |
$ 17 |
$ 21 |
$ 0 |
- |
Malachite Innovations Inc |
$ 16 |
$ 14 |
$ 3 |
- |
Check cap Ltd |
$ 11 |
- |
$ 17 |
- |
Bioaffinity Technologies Inc |
$ 9 |
$ 0 |
$ -11 |
- |
Vyant Bio Inc |
$ 6 |
$ 1 |
$ -23 |
- |
Invitae Corporation |
$ 5 |
$ 482 |
$ -1,441 |
1,500 |
Evolutionary Genomics Inc |
$ 5 |
$ 0 |
$ -4 |
- |
Halberd Corporation |
$ 4 |
- |
$ 0 |
- |
Opgen inc |
$ 4 |
$ 3 |
$ -26 |
- |
Ispecimen inc |
$ 3 |
$ 10 |
$ -11 |
- |
Onemednet Corporation |
$ 2 |
- |
$ -4 |
- |
Foxo Technologies Inc |
$ 2 |
$ 1 |
$ -115 |
- |
Grapefruit Usa Inc |
$ 1 |
$ 0 |
$ -4 |
- |
Advanced Container Technologies Inc |
$ 1 |
$ 5 |
$ -1 |
22 |
Biocept Inc |
$ 0 |
- |
$ -39 |
135 |
U s Stem Cell Inc |
$ 0 |
$ 0 |
$ -3 |
- |
Hh and l Acquisition Co |
- |
- |
$ -1 |
- |
Burning Rock Biotech Limited |
- |
$ 82 |
$ -141 |
- |
Genetron Holdings Ltd |
- |
$ 94 |
$ -118 |
862 |
Aclarion Inc |
- |
$ 0 |
$ -4 |
- |
Medical Laboratories Industry |
$ 270,800 |
- |
$ 2,131 |
382,633 |
Recent News from Medical Laboratories Industry |
Exagen Inc
Exagen Inc (Nasdaq: XGN) has shown significant signs of weakness in its latest financial report for the fourth quarter of 2023. Despite a decrease in the loss per share compared to the previous year, the company still reported a loss of $-0.30 per share. This is only a slight improvement from the loss of $-0.83 per share in the same period a year prior.
|
|
Product Service News
Natera, a leading pioneer in cell-free DNA testing, has joined forces with the Fédération Francophone de Cancérologie Digestive and CHU Dijon Bourgogne for the groundbreaking CIRCULATE-PRODIGE-70 study. This phase III clinical trial, conducted in France, aims to evaluate the potential benefits of Signatera, Natera's innovative molecular residual disease (...
|
|
Product Service News
Charles River Laboratories and Navega Therapeutics Enter Collaboration for Gene Therapy ManufacturingWILMINGTON, Mass. - Charles River Laboratories International, Inc. and Navega Therapeutics, Inc. have announced a comprehensive gene therapy manufacturing collaboration. As part of Charles River's Cell and Gene Therapy (CGT) Accelerator Program (CAP), Nave...
|
|
Product Service News
New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of DiseaseA recent publication by the Kidney Disease Improving Global Outcomes (KDIGO) organization has introduced a updated clinical practice guideline for the Evaluation and Management of Chronic Kidney Disease (CKD). The guideline, slated for implementation...
|
|
Management Announcement
Chronic Kidney Disease (CKD) affects millions of people worldwide and imposes a significant burden on healthcare systems globally. As we enter a new era of personalized medicine, risk prediction and tailored treatment plans are crucial in managing this complex and widespread condition. The inclusion of KidneyIntelX in the Final KDIGO 2024 Clinic...
|
|
Enzo Biochem Inc
Enzo Biochem Inc, a medical laboratories company, experienced a stable stock performance in March 2024 with no change in its share price. However, this brings the share price to a decrease of 11.33% in the first quarter of 2024. Additionally, the stock is currently trading only 33% above its 52-week low. For the financial second quarter of 2024, Enzo ...
|
|
Ispecimen Inc
iSpecimen Inc. (Nasdaq: ISPC) is a pioneering online marketplace that connects scientists with healthcare specimen providers for research purposes. The company, headquartered in Lexington, Massachusetts, has recently announced that it will unveil its full-year financial results for the period ending December 31, 2023, on March 13, 2024. Stakeholders are e...
|
|
Product Service News
In a significant stride towards revolutionizing cancer screening and diagnostics, Exact Sciences Corp. has announced the publication of the BLUE-C study results in The New England Journal of Medicine. The peer-reviewed study titled Next-Generation Multitarget Stool DNA Test for Colorectal Cancer Screening presents groundbreaking findings that highlight th...
|
|
Maxcyte Inc
Maxcyte Inc, a leading cell-engineering focused company, recently announced its fourth quarter and full year financial results for 2023. The company reported a surge in revenue by 26.087% to $15.66 million from the same reporting period a year before. However, it also experienced diminishing returns with a net shortfall of $-0.05 per share. Despite th...
|
|
Financing Agreement
Los Angeles, March 12, 2024 - RadNet, Inc. (NASDAQ: RDNT), a leading provider of cost-effective outpatient diagnostic imaging services, has recently announced the completion of its underwritten public offering of common stock. The offering included 5,232,500 shares of common stock at a price of $44.00 per share, with the underwriters exercising ...
|
|
|
|
|
|